Kangmei Pharmaceutical Co (SHSE:600518) Cyclically Adjusted FCF per Share: ¥-0.24 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600518 Kangmei Pharmaceutical Co Ltd SHSE:600518
51 GF Score
Price ¥1.36
GF Value ¥1.47
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Kangmei Pharmaceutical Co Cyclically Adjusted FCF per Share?

Kangmei Pharmaceutical Co SHSE:600518 -2.16% 51 Cyclically Adjusted FCF per Share is ¥-0.24 as of Mar. 2026. GuruFocus rates SHSE:600518 with a GF Score™ of 51/100 and a GF Value™ of ¥1.47 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Kangmei Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was ¥-0.004. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥-0.24 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -6.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -2.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Kangmei Pharmaceutical Co was 15.10% per year. The lowest was -35.70% per year. And the median was -6.60% per year.

As of today (2026-08-21), Kangmei Pharmaceutical Co's current stock price is ¥1.36. Kangmei Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ¥-0.24. Kangmei Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is .


Kangmei Pharmaceutical Co  (SHSE:600518) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Kangmei Pharmaceutical Co Cyclically Adjusted FCF per Share Related Terms


Kangmei Pharmaceutical Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Kangmei Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kangmei Pharmaceutical Co Cyclically Adjusted FCF per Share Chart

Kangmei Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.19 -0.19 -0.22 -0.25 -0.23

Kangmei Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 0.00 -0.26 -0.23 -0.24

SHSE:600518 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kangmei Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kangmei Pharmaceutical Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kangmei Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kangmei Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.


SHSE:600518
51GF Score
Kangmei Pharmaceutical Co Ltd SHSE:600518
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kangmei Pharmaceutical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kangmei Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.004/116.3033*116.3033
=-0.004

Current CPI (Mar. 2026) = 116.3033.

Kangmei Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.396 101.400 -0.454
201609 0.084 102.400 0.095
201612 0.169 102.600 0.192
201703 0.251 103.200 0.283
201706 -0.085 103.100 -0.096
201709 0.044 104.100 0.049
201712 -1.096 104.500 -1.220
201803 -0.445 105.300 -0.492
201806 -0.993 104.900 -1.101
201809 -0.370 106.600 -0.404
201812 0.374 106.500 0.408
201903 0.097 107.700 0.105
201906 0.290 107.700 0.313
201909 0.191 109.800 0.202
201912 -0.115 111.200 -0.120
202003 0.032 112.300 0.033
202006 0.024 110.400 0.025
202009 0.085 111.700 0.089
202012 0.002 111.500 0.002
202103 0.005 112.662 0.005
202106 0.004 111.769 0.004
202109 -0.006 112.215 -0.006
202112 0.002 113.108 0.002
202203 -0.014 114.335 -0.014
202206 -0.009 114.558 -0.009
202209 -0.002 115.339 -0.002
202212 -0.030 115.116 -0.030
202303 -0.018 115.116 -0.018
202306 0.000 114.558 0.000
202309 -0.006 115.339 -0.006
202312 -0.011 114.781 -0.011
202403 -0.046 115.227 -0.046
202406 0.000 114.781 0.000
202409 -0.003 115.785 -0.003
202412 -0.007 114.893 -0.007
202503 -0.013 115.116 -0.013
202506 0.000 114.907 0.000
202509 0.013 115.471 0.013
202512 -0.009 115.832 -0.009
202603 -0.004 116.303 -0.004

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥-0.24 mean?
Kangmei Pharmaceutical Co (SHSE:600518) has a Cyclically Adjusted FCF per Share of ¥-0.24 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Kangmei Pharmaceutical Co and its competitors.
Is Kangmei Pharmaceutical Co's Cyclically Adjusted FCF per Share too high?
Kangmei Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥-0.24. Overall, Kangmei Pharmaceutical Co has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kangmei Pharmaceutical Co's Cyclically Adjusted FCF per Share compare to ZTS?
Kangmei Pharmaceutical Co's Cyclically Adjusted FCF per Share of ¥-0.24 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Kangmei Pharmaceutical Co and its competitors. Kangmei Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥-0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kangmei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kangmei Pharmaceutical Co (SHSE:600518) is currently considered Fairly Valued. The stock's GF Value™ is ¥1.47, compared to a current price of ¥1.36 — trading 7.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥-0.24. Kangmei Pharmaceutical Co's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Kangmei Pharmaceutical Co (SHSE:600518), the current Cyclically Adjusted FCF per Share is ¥-0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kangmei Pharmaceutical Co (SHSE:600518) Overvalued in 2026?

Based on GuruFocus' analysis, Kangmei Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥1.36 is trading 7.5% below its estimated GF Value™ of ¥1.47. GuruFocus considers Kangmei Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600518:

  • Cyclically Adjusted FCF per Share: ¥-0.24
  • GF Value™: ¥1.47 vs. price of ¥1.36 (7.5% below fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kangmei Pharmaceutical Co Business Description

Address Taike Road, Xiameilin, Futian District, Guangdong, Shenzhen, CHN, 518000
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs, and medical devices, modern pharmaceutical logistics system. The company is also engaged in medical equipment, property leasing and sales, and other services.
51GF Score

Get the complete analysis for SHSE:600518

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥1.36
Price
¥1.47
GF Value